Overview


FutureWise Market Research has instantiated a report that provides an intricate analysis of Primary Biliary Cirrhosis Drug Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis of market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of the market.
According to the research study conducted by FutureWise research analysts, the Primary Biliary Cirrhosis Drug Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the Primary Biliary Cirrhosis Drug Market along with the growth opportunities present across this business vertical.



Major players included in the Primary Biliary Cirrhosis Drug Market are
• ALBIREOPHARMA
• CYMABAY THERAPEUTICS, INC.
• DR. FALK PHARMA GMBH
• ENANTA PHARMACEUTICALS, INC.
• GLAXOSMITHKLINE PLC
• INTERCEPT PHARMACEUTICALS, INC.
• JOHNSON
JOHNSON
• MEDIGENE AG
(Note: The list of the major players will be updated with the latest market scenario and trends)
Primary Biliary Cirrhosis Drug Market




By Type

Budesonide

FFP-104

GSK-2330672

MBX-8025

NGM-282

Others


By Application

Clinic

Hospital

Others
By Region
• North America
• Europe
Asia-Pacific
• Rest of the world
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth
• To provide with an exhaustive analysis on the Primary Biliary Cirrhosis Drug Market by type, by application and by region
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific and rest of the world
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization services offered are free of charge with purchase of any license of the report.
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1 . Years Considered for the Study
         3.2 . Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1 . Secondary Data
          1.1.1 . Key Data From Secondary Sources
         1.2 . Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Global Primary Biliary Cirrhosis Drug Market Variables, Trends
    • Scope
        1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards And Compliances
  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Global Primary Biliary Cirrhosis Drug Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Global Primary Biliary Cirrhosis Drug Market, By Type Historical Analysis and Forecast 2020-2027 (USD Million)
    •   1. Budesonide
        2. FFP-104
        3. GSK-2330672
        4. MBX-8025
        5. NGM-282
        6. Others
  • 8.   Global Primary Biliary Cirrhosis Drug Market, By Application Historical Analysis and Forecast 2020-2027 (USD Million)
    •   1. Clinic
        2. Hospital
        3. Others
  • 9.   North America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) along with expected regulatory needs
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
           2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2020-2027
  • 10.   Europe Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
         2.1. Germany
          2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Switzerland
         2.9. Rest of Western Europe
  • 11.   Asia Pacific Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) - along with expected regulatory needs
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
         2.1. Japan
         2.2. China
         2.3. Singapore
         2.4. India
         2.5. Australia and New Zealand
         2.6. ASEAN
         2.7. South Korea
         2.8. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027
  • 12.   Rest of the World Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) along with expected regulatory needs
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
         2.1. Saudi Arabia
         2.2. UAE
         2.3. South Africa
         2.4. Egypt
        3. Market Size (USD Million) Forecast for MEA 2020-2027
  • 13.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Type and Technology Portfolio, Financial Layouts)
    •   1. ALBIREOPHARMA
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
         2. CYMABAY THERAPEUTICS, INC.
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
         3. DR. FALK PHARMA GMBH
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
         4. ENANTA PHARMACEUTICALS, INC.
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. GLAXOSMITHKLINE PLC
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
         6. INTERCEPT PHARMACEUTICALS, INC.
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. JOHNSON
      JOHNSON
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. MEDIGENE AG
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
  • 14.   FutureWise SME key takeaway points for Client
Partner

Our Clients